Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 94.9M |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| P/B | 2.6 |
| P/S (ttm) | 115.2 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 6% |
| Held by Institutions % | 68% |
| 1 Day Vol Adjusted Return | -1.5 |
| 1 Month Vol Adjusted Return | -2.2 |
| 3 Month Vol Adjusted Return | -7.3 |
| 6 Month Vol Adjusted Return | -6.9 |
| 20 Days SMA Price ZScore | -1.7 |
| 50 Days SMA Price ZScore | -1.9 |
| 12 -26 Days PPO | -4.9 |
| 1 Month Average Short Volume Ratio | 31.8 |
| 1 Day Volume Change ZScore | 0.1 |
| 1 Month Daily Vol | 6.6 |
Stock news
Viewing insider transactions for Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) over the last year, we see that...
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021. A pre-recorded corporate presentation will be available on-demand beginning on Thursday, Nov. 18 and will remain available for 30 days in the investor section of the Cyclerion w
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS); Topline clinical results expected in H1 2022 CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to d
Infused with $27 million from General Catalyst and Casdin Capital, Beacon Biosignals is planning to capitalize on the resurgence in neuroscience across the biotech field.
Truist analyst Joon Lee has initiated coverage of Cyclerion Therapeutics Inc (NASDAQ: CYCN) with a Buy rating and price target of $14, suggesting a massive 374% upside. The development of drugs targeting the brain's nitric oxide (NO) system is "ripe for therapeutic intervention," the analyst tells investors. Lee contends that Cyclerion's lead drug, CY6463, can successfully enhance the NO signaling in the brain. Lee adds that CY6463 is currently in three signal finding clinical studies - MELAS, A
In this article, we discuss the top stocks recently acquired by David Greenspan’s Slate Path Capital according to analysts. If you want to skip our detailed analysis of Greenspan’s history, investment philosophy, and hedge fund performance, go directly to David Greenspan’s Slate Path Capital is Buying These 5 Stocks. David Greenspan instilled his efforts at […]
Every investor in Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) should be aware of the most powerful shareholder groups...